Form 4: GUIDED THERAPEUTICS Director Alan Grujic Acquires 110,000 Stock Options

Alan Grujic, a Director at GUIDED THERAPEUTICS INC, has acquired 110,000 stock options with an exercise price of $0.14, vesting over a period until June 2028.

Summary

• Alan Grujic, a Director of GUIDED THERAPEUTICS INC (GTHP), acquired 110,000 derivative securities in the form of stock options.
• The transaction date for this acquisition was June 3, 2025.
• Each stock option has an exercise price of $0.14.
• The options entitle the holder to acquire 110,000 shares of Common Stock.
• One-fourth of the shares subject to the award vested on June 3, 2025.
• The remaining shares will vest monthly, commencing on September 3, 2025, contingent on Mr. Grujic's continued service.
• The award is scheduled to be fully vested by June 2, 2028.
• The expiration date for these stock options is June 2, 2035.
• Following this transaction, Mr. Grujic beneficially owns 110,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally viewed as a positive signal of alignment with shareholder interests and confidence in the company's future, although it is a routine compensation event and not indicative of extraordinary news.

Positives

• The acquisition of stock options by a director aligns management's interests with those of shareholders, as the value of the options increases with the company's stock price.
• The grant of options can be seen as a form of long-term incentive for the director, encouraging continued service and performance.

Future Outlook

The vesting schedule for the stock options, extending until June 2, 2028, indicates an expectation of Alan Grujic's continued service as a director for GUIDED THERAPEUTICS INC.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and medical device industries, serving as a form of non-cash compensation and a mechanism to align the interests of board members with long-term shareholder value creation. This is a standard compensation event.

Comparison to Industry Standards

• Equity compensation, such as stock options, is a widely adopted practice across publicly traded companies, including those in the medical technology sector like GUIDED THERAPEUTICS INC.
• The vesting schedule, with a portion vesting immediately and the remainder over several years, is typical for director or executive equity grants, aiming to incentivize long-term commitment and performance.
• The exercise price of $0.14, while specific to GTHP's current valuation, is consistent with options granted at or near the market price on the grant date, a common structure for compensatory options.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive signal of insider confidence and aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders if the stock price increases.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Alan Grujic's continued service to GUIDED THERAPEUTICS INC is required for the remaining stock options to vest monthly until June 2, 2028.

Key Dates

Recommendation

Keywords

GUIDED THERAPEUTICS, GTHP, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Alan Grujic, SEC Form 4